DelveInsight’s “Acute Renal Failure (ARF) (Acute Kidney Injury) Market Report 2030“ delivers an in-depth understanding of the Acute Renal Failure (ARF) (Acute Kidney Injury), historical and forecasted epidemiology as well as the Acute Renal Failure (ARF) (Acute Kidney Injury) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017-2030
Acute Renal Failure (ARF) (Acute Kidney Injury) Disease Understanding and Treatment Algorithm
Overview of the report
AKI is characterized by a rapid fall in glomerular filtration rate, clinically manifest as an abrupt and sustained rise in urea and creatinine. Life-threatening consequences include volume overload, hyperkalaemia, and metabolic acidosis. As per the American Kidney Foundation organization, AKI was formerly called Acute Kidney Injury. The disease leads to an abrupt loss of kidney function, leading to the retention of waste products, electrolyte disturbances, and volume status changes.
Acute Kidney Injury is classified into three different phases including prerenal, postrenal and intrinsic renal. Pre-renal ARI is characterized by the inadequate blood circulation to the kidneys, which leaves them to clean the body properly. Post-renal is characterized by acute obstruction to urinary flow which increases intratubular pressure and decreases GFR. Intrinsic AKI is the third type, which shows direct damage to kidneys by inflammation, toxins, drugs, and infections. The risk factors associated with AKI include age, exposure to nephrotoxins, family history, race and ethnicity, gender and others.
The DelveInsight Acute Renal Failure market report gives a thorough understanding of the Acute Renal Failure (ARF) (Acute Kidney Injury) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
Acute Renal Failure (ARF) Epidemiology
The Acute Renal Failure (ARF) epidemiology division provide insights about historical and current Acute Renal Failure (ARF) (Acute Kidney Injury) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
- DelveInsight also estimates higher Diagnosed Discharge Cases of AKI in the United States with 532,830 diagnosed discharge cases found in 2017.
- According to KIDGO staging; stage II AKI corresponds to the relatively higher diagnosed discharge population with 223,789 cases in 2017 in the United States.
Key companies involved:
1. Angion Biomedica
2. Quark Pharmaceutical
3. Astellas Pharma
5. Conestat alfa; PharmingTechnologies
6. AM Pharma
Acute Renal Failure (ARF) (Acute Kidney Injury) Market Outlook
Acute kidney injury (AKI) or acute renal failure (AKI) is a condition characterized by minor or complete loss of kidney function due to a sudden injury to kidneys. AKI is different from chronic kidney disease, wherein the kidney function is lost over a period of time. The disease generally occurs as a complication of another serious disease and is more common in the geriatric population that suffers from various other diseases.
The global burden of acute kidney injury has increased over the years. Among the 7 major markets, the United States has reported having maximum incident cases of AKI. Though the incident of AKI is high across the US, but the condition is often undiagnosed, ultimately leading to lower treatable pool (when compared to the total incident population of the disease) that contributes to the market size of AKI.
Currently there are no targeted pharmacotherapies approved for the treatment of AKI. At present, the therapeutic market size of acute kidney injury in the United States is mainly accounted by use of Renal Replacement Therapy (RRT) and off-label drugs which includes various classes such as ACE inhibitors, Angiotensin II-Receptor Blockers (ARBs), Diuretics and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
The Acute Renal Failure market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Acute Renal Failure (ARF) (Acute Kidney Injury) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
According to DelveInsight, Acute Renal Failure (ARF) (Acute Kidney Injury) market in 7MM is expected to change in the study period 2017-2030.
Scope of the Report
- The report covers the descriptive overview of Acute Renal Failure (ARF) (Acute Kidney Injury), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Acute Renal Failure (ARF) (Acute Kidney Injury) epidemiology and treatment
- An all-inclusive account of both the current and emerging therapies for Acute Renal Failure (ARF) (Acute Kidney Injury) are provided
- A detailed review of Acute Renal Failure (ARF) (Acute Kidney Injury) market; historical and forecasted
- The report provides an edge while developing business strategies
Request for sample pages of the report: https://www.delveinsight.com/sample-request/acute-renal-failure-arf-acute-kidney-injury-market
Table of contents
1 Key Insight
2 Executive Summary of Acute renal failure (Acute kidney injury)
3 Acute renal failure (Acute kidney injury) Market Overview at a Glance
4 Disease Background and Overview: Acute renal failure (Acute kidney injury)
5 Case Reports
6 Acute renal failure (Acute kidney injury) Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Acute renal failure (Acute kidney injury) Treatment and Medical Practices
11 Unmet needs
12 Acute renal failure (Acute kidney injury) Marketed Drugs
13 Acute renal failure (Acute kidney injury) Emerging Drugs
14 Acute renal failure (Acute kidney injury) 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Acute renal failure (Acute kidney injury) Market Drivers
19 Acute renal failure (Acute kidney injury) Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
23 DelveInsight Capabilities
25 About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States